Hospice Medical Director Summit 2026

Scottsdale, AZ US

October 10, 2026 to October 11, 2026

The Addus HomeCare Hospice Medical Director Summit is an educational and collaborative meeting for hospice medical directors and area operations leaders, held October 9–12, 2026, at The Boulders Resort & Spa in Scottsdale, Arizona. The summit brings together leaders from across our hospice programs to strengthen clinical practice, exchange expertise, and support high-quality, patient-centered end-of-life care.

The educational program combines expert presentations, interdisciplinary discussion, and a roundtable. Planned topics include pain management across the chronic, palliative, and hospice care continuum; buprenorphine or methadone therapy and deprescribing; hospice eligibility and certification of terminal illness documentation; goals-of-care conversations; and legal and regulatory considerations. Sessions are intended to support clinical decision-making, effective interdisciplinary collaboration, and the application of best practices in hospice care.

The summit also includes separately identified organizational updates, technology discussions, and appreciation activities. CME credit is being sought for eligible educational sessions, subject to the accredited provider’s review and approval.

Target Audience

Hospice medical directors, associate medical directors, and area operations leaders involved in the clinical oversight and delivery of hospice and palliative care. The educational content is primarily designed for physicians responsible for symptom management, hospice eligibility assessment, certification of terminal illness, interdisciplinary care planning, and goals-of-care discussions.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

Apply patient-centered pain management strategies across chronic, palliative, and hospice care settings.
Evaluate the appropriate use of buprenorphine and methadone based on patient needs, treatment goals, and safety considerations.
Identify opportunities for deprescribing by assessing medication benefits, burdens, and alignment with goals of care.
Assess hospice eligibility and develop clear certification of terminal illness (CTI) documentation that supports the clinical rationale and applicable requirements.
Use interdisciplinary collaboration and goals-of-care conversations to align care plans with patient and family preferences.
Recognize relevant legal and regulatory requirements and apply them to hospice medical director practice.

Commercial Support
There is no commercial support for this activity.

Course summary

Available credit:

4.25 AMA PRA Category 1 Credit™
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
4.25 AMA PRA Category 1 Credit™ Non-MD
Non-Physicians Seeking AMA Credit
AKH Inc., Advancing Knowledge in Healthcare designates this Live Activity for a maximum of 4.25 AMA PRA Category 1 Credit(s)™.

Course opens:

10/10/2026

Course expires:

12/31/2026

Event starts:

10/10/2026 - 7:00am EDT

Event ends:

10/11/2026 - 11:59pm EDT

Cost:

$0.00

Add to calendar:

Rating:

Boulders Resort & Spa Scottsdale

34631 N Tom Darlington Dr

Scottsdale, AZ 85262

United States

All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.

Reviewer(s)